HC Wainwright & Co. Maintains Buy Rating for Vericel: Here's What You Need To Know
Portfolio Pulse from Benzinga Insights
HC Wainwright & Co. has reaffirmed its Buy rating on Vericel (NASDAQ:VCEL) and increased its price target from $44.50 to $46.00. Vericel's shares are currently trading at $38.24, and the new price target suggests a potential upside of 20.29%. Vericel is a biopharmaceutical company focused on cell therapy products for sports medicine and severe burn care.
January 16, 2024 | 5:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. maintains a Buy rating on Vericel and raises the price target to $46, suggesting a 20.29% potential increase from the current price.
The reaffirmation of a Buy rating and an increased price target by a reputable analyst firm like HC Wainwright & Co. typically instills confidence in investors and can lead to a positive short-term impact on the stock price. The new price target represents a significant potential upside, which may attract investor interest and drive up the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100